Drugs for Cough: Antitussives and Expectorants

Introduction/Overview

Cough is a protective reflex that expels irritants and secretions from the airways. It represents a common symptom encountered in primary care, urgent care, and specialized respiratory settings. The management of cough often requires pharmacologic intervention, particularly when the reflex is persistent, distressing, or contributes to secondary complications such as aspiration or sleep disturbance. Antitussives and expectorants constitute the main pharmacologic classes employed to alleviate cough, each targeting distinct pathophysiologic mechanisms. Understanding the pharmacology of these agents is essential for optimizing therapeutic outcomes while minimizing adverse effects and drug interactions.

Learning objectives

• Identify the principal drug classes used to treat cough and their therapeutic indications.
• Explain the pharmacodynamic and pharmacokinetic principles governing antitussive and expectorant activity.
• Recognize common adverse effects, contraindications, and potential drug interactions associated with these agents.
• Apply evidence‑based decision‑making to select appropriate pharmacologic therapy for specific cough presentations.
• Evaluate special considerations, including pregnancy, lactation, pediatrics, geriatrics, and organ impairment, when prescribing cough medications.

Classification

Antitussives

Antitussives are subdivided according to their site of action and mechanism of action. Central antitussives act primarily within the brainstem cough centre, whereas peripheral antitussives modulate afferent sensory pathways or reduce airway irritability. The following classes are clinically relevant:

• Centrally acting antitussives – opioids (e.g., codeine, hydrocodone), non‑opioid NMDA receptor antagonists (e.g., dextromethorphan), and barbiturates (e.g., phenobarbital).
• Peripherally acting antitussives – adenosine A₂A receptor antagonists (e.g., caffeine), chloride channel blockers (e.g., cloperastine), and agents that reduce airway edema.

Expectorants

Expectorants facilitate the clearance of mucus by decreasing its viscosity or altering its composition. They are typically grouped by their chemical structure and mechanism:

• Mucolytics – thiol‑containing agents that disrupt disulfide bonds in mucus glycoproteins (e.g., acetylcysteine, carbocisteine, ambroxol).
• Secretagogues – agents that increase airway surface liquid secretion (e.g., d‑mannitol, potassium iodide).
• Combined mucolytic‑secretagogue agents – formulations that incorporate both activities (e.g., guaifenesin‑based preparations).

Mechanism of Action

Centrally Acting Antitussives

Opioid antitussives, such as codeine, undergo hepatic metabolism to morphine, which binds µ‑opioid receptors located in the medullary cough centre. Activation of these receptors dampens neuronal excitability, thereby raising the threshold required for cough reflex initiation. Non‑opioid centrally acting agents, notably dextromethorphan, exhibit affinity for N‑methyl‑D‑aspartate (NMDA) receptors and sigma‑1 receptors, modulating glutamatergic neurotransmission and attenuating cough reflex sensitivity. Phenobarbital, a barbiturate, enhances gamma‑aminobutyric acid (GABA)ergic inhibition within the central nervous system, providing a nonspecific suppressant effect on the cough pathway.

Peripherally Acting Antitussives

Caffeine functions as a competitive antagonist of adenosine A₂A receptors on airway sensory C‑fiber afferents. By blocking adenosine‑mediated activation, caffeine reduces the afferent signal to the cough centre. Cloperastine, a chloride channel blocker, inhibits neuronal depolarization in the vagal afferents, thereby diminishing cough reflex activation. Additionally, these agents may exert antitussive effects by decreasing airway edema or modulating local inflammatory mediators.

Expectorants

Thiol‑containing mucolytics, such as acetylcysteine and carbocisteine, contain free sulfhydryl groups that reduce disulfide bonds between mucin glycoproteins. The resulting depolymerization decreases mucus viscosity and facilitates expectoration. Ambroxol, a synthetic derivative of bromhexine, possesses both mucolytic and immunomodulatory properties; it enhances surfactant secretion and modulates cytokine release, thereby improving mucus clearance. Secretagogues like d‑mannitol act osmotically to draw water into the airway lumen, increasing airway surface liquid and promoting mucus transport. Guaifenesin is believed to increase the volume of airway secretions and thin mucus, although the precise molecular target remains uncertain. Agents combining mucolytic and secretagogue actions may deliver synergistic benefits in conditions characterised by thick, tenacious mucus.

Pharmacokinetics

Centrally Acting Antitussives

Codeine: Absorption is rapid, with peak plasma concentrations reached within 30–60 minutes. Approximately 10–15 % of the dose undergoes O‑demethylation by CYP2D6 to morphine, the active metabolite. The remaining dose is glucuronidated to codeine‑3‑glucuronide. The half‑life averages 3–4 hours, but variability depends on CYP2D6 genotype. Distribution is extensive; the drug crosses the blood‑brain barrier and placenta. Excretion is primarily renal, with conjugated metabolites excreted in urine. Dose modifications are necessary in hepatic impairment and for CYP2D6 ultra‑rapid metabolizers to mitigate risk of morphine‑related toxicity.

Dextromethorphan: Oral bioavailability is approximately 20 % due to first‑pass metabolism; peak concentrations occur at 1–2 hours. The drug is metabolised by CYP2D6 to dextrorphan, a potent NMDA antagonist. The elimination half‑life is 3–4 hours, with an extended terminal phase of up to 8 hours. Dextromethorphan distributes widely, achieving therapeutic concentrations in the central nervous system. Renal excretion accounts for 50–60 % of the dose, primarily as glucuronide conjugates. Genetic polymorphisms in CYP2D6 influence plasma levels and therapeutic response.

Phenobarbital: Rapid absorption with peak plasma levels within 1–2 hours. Phenobarbital is highly protein‑bound (≈90 %) and distributes extensively into tissues, including the brain. Metabolism occurs via hepatic oxidation and glucuronidation, producing inactive metabolites. The terminal half‑life ranges from 12 to 24 hours, but accumulation may occur with repeated dosing due to enzyme induction. Excretion is predominantly renal. Dose adjustments are advisable in hepatic dysfunction and in patients with reduced renal clearance.

Peripherally Acting Antitussives

Caffeine: Rapid absorption with peak concentrations at 30–60 minutes. Metabolism via CYP1A2 results in paraxanthine, theobromine, and theophylline. The half‑life is approximately 3–5 hours in healthy adults, extending in elderly and hepatic impairment. Caffeine is widely distributed and crosses the placenta and breast milk. Excretion is mainly renal, with a small proportion eliminated via bile.

Cloperastine: Limited data are available; it is absorbed orally, with peak levels around 1–2 hours. Metabolism involves hepatic oxidation, and the drug is excreted through both renal and fecal routes. The half‑life is approximately 4–5 hours. Due to sparse pharmacokinetic data, dosing recommendations rely on clinical response rather than precise plasma concentrations.

Expectorants

Guaifenesin: Rapid absorption; peak plasma concentration occurs within 1 hour. Metabolism occurs via hepatic glucuronidation. The elimination half‑life is around 2–3 hours. Guaifenesin is extensively distributed, but its concentration in airway secretions is limited by its hydrophilic nature. Renal excretion accounts for the majority of elimination.

Acetylcysteine: Oral bioavailability is low (<10 %); intravenous administration achieves higher serum concentrations. Metabolism involves conjugation with glutathione and subsequent oxidation. The half‑life is about 5 hours. Acetylcysteine distributes into tissues, including the lungs, and is excreted predominantly by the kidneys. Intravenous dosing is preferred in acute settings, whereas oral dosing is used for chronic conditions.

Carbocisteine: Oral absorption is efficient; peak plasma concentrations are reached within 1–2 hours. Metabolism involves conjugation and oxidation, forming active metabolites. The elimination half‑life is approximately 3–4 hours. Carbocisteine is distributed in the lung interstitium and excreted via the kidneys.

Ambroxol: Rapid absorption with peak levels at 1–2 hours. Metabolism is mediated by CYP2D6 and CYP3A4. The half‑life ranges from 6 to 12 hours, depending on dose and patient factors. Ambroxol is highly lipophilic, allowing extensive penetration into lung tissue. Renal excretion accounts for the majority of elimination.

d‑Mannitol: Administered orally or intravenously; absorption is rapid. The drug is not metabolised and is excreted unchanged by the kidneys. The half‑life is approximately 2–3 hours. d‑Mannitol is osmotically active and remains in the extracellular fluid, thereby increasing airway surface liquid.

Therapeutic Uses/Clinical Applications

Antitussives

Central antitussives are indicated for acute, non‑productive cough associated with upper respiratory tract infections, post‑nasal drip, or mild bronchitis. Codeine and dextromethorphan are commonly prescribed for symptomatic relief, with dose titration guided by patient response and tolerability. Phenobarbital, though less frequently used, may be employed in refractory cases or when adjunctive sedation is required.

Peripherally acting antitussives are primarily used for coughs with significant airway irritation or edema, such as in allergic rhinitis or asthma exacerbations. Caffeine may be added to cough preparations to provide a mild stimulant effect, while cloperastine is reserved for specific indications where chloride channel blockade is advantageous.

Expectorants

Expectorants are most effective in productive coughs characterized by thick, viscous secretions. Guaifenesin is widely used for acute bronchitis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD). Mucolytics such as acetylcysteine and carbocisteine reduce mucus viscosity and are standard therapy in cystic fibrosis, COPD, and severe bronchiectasis. Ambroxol, with its dual mucolytic and anti‑inflammatory properties, is indicated in chronic bronchitis and post‑viral coughs where mucus hypersecretion persists.

Secretagogues like d‑mannitol are employed in patients with cystic fibrosis or severe COPD to enhance mucociliary clearance. Combined mucolytic‑secretagogue preparations may be preferred when both mucus viscosity reduction and fluid augmentation are necessary.

Off‑label uses include guaifenesin for dry cough, where the hypothetic effect on mucus hydration may alleviate irritation. Acetylcysteine is sometimes used as a pre‑emptive therapy in patients undergoing bronchoscopy or in the management of acute exacerbations of COPD.

Adverse Effects

Antitussives

Codeine frequently causes constipation, nausea, dizziness, and sedation. Respiratory depression is a serious risk, especially in opioid‑naïve patients or when combined with other CNS depressants. The risk is heightened in patients with hepatic impairment, where morphine accumulation may occur. Dextromethorphan is generally well tolerated, but paradoxical agitation or hallucinations can arise at high doses. Serotonin syndrome may develop when combined with serotonergic agents. Phenobarbital can lead to sedation, ataxia, and cognitive impairment; it also induces hepatic enzymes, potentially altering the metabolism of concomitant drugs.

Expectorants

Guaifenesin is usually safe, with mild gastrointestinal upset and rash reported rarely. Acetylcysteine may provoke nausea, vomiting, and, on rare occasions, anaphylactoid reactions; intravenous infusion requires pre‑medication in patients with a history of hypersensitivity. Carbocisteine commonly causes gastrointestinal disturbances, including abdominal pain and nausea. Ambroxol is generally well tolerated, but rare cases of skin rash and pruritus have been documented. d‑Mannitol can induce osmotic diuresis, leading to dehydration and electrolyte imbalance, particularly in patients with renal dysfunction.

No antitussive currently bears a black‑box warning; however, codeine’s risk of respiratory depression and potential for dependency necessitates cautious use. Expectorants lack black‑box warnings, but vigilance for hypersensitivity reactions with acetylcysteine is advisable.

Drug Interactions

Antitussives

• Codeine: Concomitant use with CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) can decrease morphine formation, reducing analgesic and antitussive efficacy. CYP2D6 inducers (e.g., carbamazepine, rifampin) may increase morphine levels, raising the risk of respiratory depression. Opioid‑based analgesics, benzodiazepines, and other CNS depressants potentiate sedation.
• Dextromethorphan: Interactions with monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), and serotonin‑specific reuptake inhibitors (SSRIs) can precipitate serotonin syndrome. CYP2D6 inhibitors reduce dextrorphan formation, potentially increasing dextromethorphan exposure. Concurrent use with ketamine may enhance dissociative effects.
• Phenobarbital: Induces CYP3A4 and CYP2B6, accelerating the metabolism of co‑administered drugs such as warfarin, oral contraceptives, and antiretroviral agents. Co‑administration with other CNS depressants heightens sedation risk.

Expectorants

• Guaifenesin: Minimal clinically significant interactions; may theoretically affect the absorption of drugs with high first‑pass metabolism due to altered gastric pH.
• Acetylcysteine: Sulfonamides may compete for renal excretion, potentially reducing acetylcysteine clearance. Concurrent use with nitrofurantoin can precipitate hemolysis in G6PD‑deficient patients.
• Carbocisteine: No major interactions reported; however, it may reduce the bioavailability of drugs requiring acidic gastric pH.
• Ambroxol: Potential interaction with CYP2D6 inhibitors or inducers, affecting its own metabolism. Co‑administration with anticholinergic agents may intensify dry mouth.
• d‑Mannitol: May alter the pharmacokinetics of drugs excreted unchanged by the kidneys by increasing renal clearance.

Special Considerations

Pregnancy and Lactation

• Codeine: Classified as pregnancy category B, but morphine metabolites can cross the placenta, potentially causing neonatal respiratory depression. Breastfeeding is discouraged due to opioid excretion in milk.
• Dextromethorphan: Category A; however, caution is advised, especially in late pregnancy, due to potential CNS effects on the fetus. Breastfeeding is generally considered safe at therapeutic doses.
• Phenobarbital: Category D; fetal exposure may result in neonatal jaundice and hypotonia. Breastfeeding is contraindicated during active therapy.
• Guaifenesin: Category C; limited data exist, but it is generally considered safe in pregnancy. Lactation appears acceptable at therapeutic doses.
• Acetylcysteine: Category B; widely used to treat acetaminophen toxicity during pregnancy. Breastfeeding is considered safe.
• Carbocisteine, Ambroxol, d‑Mannitol: Generally considered safe; however, data are limited, and caution is advised in high‑dose or prolonged use.

Pediatrics and Geriatrics

In pediatric populations, dosing is weight‑based and requires careful titration to avoid respiratory depression or sedation. Codeine is contraindicated in children under 12 years due to the risk of life‑threatening respiratory depression. Dextromethorphan is recommended for children above 6 years, with age‑appropriate formulations. Expectorants are generally safe in children, but dosing adjustments are necessary for infants and toddlers. In geriatric patients, reduced hepatic and renal clearance necessitates dose reduction for codeine, dextromethorphan, and expectorants such as guaifenesin. Cognitive impairment and polypharmacy increase the risk of drug interactions and adverse events.

Renal and Hepatic Impairment

• Codeine: Hepatic dysfunction reduces morphine formation, potentially diminishing efficacy. Renal impairment may prolong elimination of the parent drug, increasing exposure.
• Dextromethorphan: Hepatic impairment leads to decreased metabolism, raising plasma concentrations and the risk of CNS toxicity. Renal dysfunction may modestly extend the half‑life.
• Phenobarbital: Hepatic impairment reduces clearance; dosing intervals should be lengthened. Renal impairment may also prolong elimination of metabolites.
• Acetylcysteine: Hepatic failure increases systemic exposure; however, intravenous administration remains the preferred route. Renal impairment necessitates monitoring for accumulation and potential toxicity.
• Carbocisteine, Ambroxol, d‑Mannitol: Renal impairment reduces clearance; dose adjustments are required. Hepatic dysfunction may influence metabolism, particularly for carbocisteine and ambroxol.

Summary/Key Points

• Antitussives are divided into centrally and peripherally acting agents; opioids and NMDA antagonists target the medullary cough centre, whereas adenosine antagonists and chloride channel blockers modulate peripheral afferent input.
• Expectorants function by reducing mucus viscosity (mucolytics), increasing airway surface liquid (secretagogues), or combining both actions; they are most effective in productive coughs.
• Pharmacokinetic variability, particularly involving CYP2D6 genotype for codeine and dextromethorphan, influences both efficacy and safety; therapeutic drug monitoring is rarely required but should be considered in high‑risk populations.
• Adverse effect profiles differ markedly: opioids carry respiratory depression risk; dextromethorphan may precipitate serotonin syndrome; mucolytics may induce gastrointestinal upset or hypersensitivity reactions.
• Drug interactions are mediated primarily through CYP450 enzymes and CNS depression pathways; careful review of concomitant medications is essential to prevent serious adverse events.
• Special populations—including pregnant women, lactating mothers, pediatrics, geriatrics, and patients with organ impairment—require tailored dosing strategies and heightened vigilance for toxicity.
• Clinical decision‑making should balance symptomatic relief with potential harm, integrating patient‑specific factors, comorbidities, and concomitant therapies.

References

1. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
7. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
8. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.